Placebo Almonertinib

DRUG2 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Non-small Cell Lung Cancer

Phase 3

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Active, not recruitingNCT04687241

Jiangsu Hansoh Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2021-04-30End: 2029-01-01Target: 192Updated: 2024-11-07

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

RecruitingNCT04951635

Jiangsu Hansoh Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2021-03-18End: 2027-01-15Target: 150Updated: 2022-06-16

Related Papers

Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.

2026-01-12

Abstract CT126: Aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: A randomized, double-blind, placebo-controlled, phase 3 trial (ARTS)

Cancer Research2025-04-25

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Journal of Clinical Oncology2023-01-31346 citations

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations

Journal of Clinical Oncology2022-05-17250 citations